By Denny Jacob
Amneal Pharmaceuticals on Monday said it received a request from the Food and Drug Administration for additional information regarding an ingredient in IPX203, a Parkinson’s disease treatment for which the company submitted a new drug application.
The pharmaceutical company said the complete response letter indicated a scientific…
Read the full article here